Baird Maintains Outperform on Abbott Laboratories, Raises Price Target to $123
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsPrice TargetHot
Baird analyst David Rescott maintains Abbott Laboratories (NYSE:ABT) with a Outperform and raises the price target from $121 to $123.
Baird analyst David Rescott maintains Abbott Laboratories (NYSE:ABT) with a Outperform and raises the price target from $121 to $123.